Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433622 | 1.00 | POLB (0.44) | POLBS1PR2MAPK1MAPTGSK3B | |
| SCHEMBL27836045 | 0.79 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL3432103 | 0.77 | WNT3A (0.44) | MAPTGSK3BMTOR | |
| SCHEMBL3433484 | 0.77 | WNT3A (0.44) | MAPTGSK3BMTOR | |
| SCHEMBL3433014 | 0.77 | MAPT (0.39) | S1PR2MAPTGSK3B | |
| SCHEMBL3433018 | 0.77 | MAPT (0.39) | S1PR2MAPTGSK3B | |
| SCHEMBL1505599 | 0.77 | MAPK1 (0.40) | MAPK1 | |
| SCHEMBL3433611 | 0.76 | S1PR2 (0.42) | S1PR2 | |
| SCHEMBL3434991 | 0.76 | S1PR2 (0.42) | S1PR2 | |
| SCHEMBL12832602 | 0.75 | MAPK1 (0.40) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| WO-2011024004-A1 | HETEROCYCLIC UREA DERIVATIVES USEFUL FOR TREATMENT OF BACTERIAL INFECTION | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| WO-2009106885-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | POLB 655/4885S1PR2 4080/4885MAPK1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.